Game-Changing Company Fighting One Of America's Most Expensive Diseases

This exceptional company is fighting a disease that millions of Americans suffer from -- including myself. Its stock soared 412% over the last five years, but it's still worth looking into today. Here's why... View Online | Add to Address Book November 22, 2014 This Week's Top Articles...   The 10 Stocks To Own For The Rest Of Your Life We believe these Forever Stocks will continue rewarding investors for years on end, crushing the market over the long run. Here's why...   Pocket A 7.5% Yield From Uncle Sam's Landlord This real estate investment trust has one of the most reliable tenants on Earth and now it is focusing on growth. Here's how...   Short Sellers Are Targeting This 'Forever Stock' If you own shares of this great company, then you need to stay abreast of the current controversy. Details here. --Sponsored--   The Secret To Triple-Digit Profits Our trades have delivered gains of 127%, 153%, even 345% gains over the last year -- no matter which way the market was heading. We've helped investors double, even triple, their income from stocks. See how we're buying red-hot stocks at a huge discount right now. Plus, get my top 3 trades now absolutely free.   A Game-Changing Company Fighting One Of America's Most Expensive Diseases This exceptional company is fighting a disease that millions of Americans suffer from -- including myself. Its stock soared 412% over the last five years, but it's still worth looking into today. Here's why...   A Defensive Play That Could Earn Triple-Digit Profits If The Market Tanks Valuations are getting stretched, and the slightest weakness could lead to a big drop. Hedge your portfolio with this play. To ensure that you receive these emails, please add us to your address book. Disclosure: StreetAuthority does not own shares in any of the securities mentioned in this article. In accordance with company policies, StreetAuthority always provides readers with at least 48 hours advance notice before buying or selling any securities in any "real money" model portfolio. Members of our staff are restricted from buying or selling any securities for one week after being featured in our advisories or on our website, as monitored by our compliance officer. StreetAuthority is a publisher of financial news and opinions. StreetAuthority is not a securities broker/dealer or an investment advisor and we do not recommend or endorse any brokers, dealers or investment advisors. This work is based on SEC filings, current events, interviews, corporate press releases and publicly available information which may contain errors. All information contained in our newsletters and/or on our website(s) should be independently verified with the companies or sources mentioned. You are responsible for your own investment decisions and should always conduct your own research and due diligence and consider obtaining professional advice before making any investment decision. This message was sent by an automated message delivery platform. Please do not reply to this email address. Any messages sent to this address will be automatically deleted. We sincerely hope that you benefit from your subscription to this complimentary newsletter, and we're willing to do whatever it takes to keep you as a satisfied subscriber. You may contact our customer service department by visiting this link. To update your subscription preferences, please click here. Copyright (c) 2014 StreetAuthority, 4601 Spicewood Springs Road, Austin, TX 78759. All rights reserved. Any reproduction or redistribution in whole or in part without StreetAuthority approval is prohibited.